MFN2 and cholangiocarcinoma: Specifically, MSL subunits were significantly upregulated in several malignancies, including cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and stomach adenocarcinoma (STAD), where their expression showed a strong positive association with immune cell infiltration (Table 2).